Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cleveland Clinic Journal of Medicine
For patients with cirrhosis facing venous thromboembolic events, the choice of anticoagulant—be it DOACs or LMWH—demands careful consideration of their unique hemostatic profile, emphasizing the need for personalized treatment strategies.
Gastroenterology February 22nd 2024
Venous thromboembolism presents a significant challenge in cancer care, with emerging evidence supporting the use of direct oral anticoagulants for improved outcomes. This highlights the evolving landscape of VTE management in oncology, stressing the importance of personalized treatment strategies.
Hematology/Oncology February 20th 2024
Recent studies challenge the traditional view of venous thromboembolism as a direct cause of unexplained fevers, emphasizing the need for comprehensive diagnostic evaluations.
Emergency Medicine January 11th 2024
Explore the complex interplay between MTHFR gene variants and thrombosis risk. This deep dive into the latest research reveals surprising insights.
Cardiology November 15th 2023
Annals of Internal Medicine
The potential of the antiviral combo in reducing the risk of thromboembolic events among post-COVID-19 patients is real. Could it pave the way for more targeted therapeutic strategies in managing post-COVID-19 conditions?
All Specialties November 8th 2023
NEJM Evidence
Reconsideration of routine thromboprophylaxis in older adults may be warranted, as the SYMPTOMS trial found no significant difference in the prevention of symptomatic venous thromboembolism when comparing low-molecular-weight heparin with a placebo. Further research is needed to validate these results and determine the best strategies for VTE prevention in this demographic.
Cardiology July 3rd 2023